Proteomic discovery in diabetic kidney disease-to what end?

[1]  A. Galecki,et al.  Results of untargeted analysis using the SOMAscan proteomics platform indicates novel associations of circulating proteins with risk of progression to kidney failure in diabetes. , 2022, Kidney international.

[2]  Stephen A. Williams,et al.  A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk , 2022, Science Translational Medicine.

[3]  P. Kimmel,et al.  Longitudinal TNFR1 and TNFR2 and Kidney Outcomes: Results from AASK and VA NEPHRON-D , 2022, Journal of the American Society of Nephrology : JASN.

[4]  M. Nangaku,et al.  Lysophosphatidylcholine mediates fast decline in kidney function in diabetic kidney disease , 2021, Kidney International.

[5]  T. Libermann,et al.  Circulating proteins protect against renal decline and progression to end-stage renal disease in patients with diabetes , 2021, Science Translational Medicine.

[6]  V. Nair,et al.  Comprehensive Search for Novel Circulating miRNAs and Axon Guidance Pathway Proteins Associated with Risk of ESKD in Diabetes , 2021, Journal of the American Society of Nephrology : JASN.

[7]  Mark R. Hurle,et al.  Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases , 2019, bioRxiv.

[8]  Jennifer K. Sun,et al.  A Signature of Circulating Inflammatory Proteins and Development of End Stage Renal Disease in Diabetes , 2019, Nature Medicine.

[9]  Robert E. Gerszten,et al.  Emerging Affinity-Based Proteomic Technologies for Large-Scale Plasma Profiling in Cardiovascular Disease , 2017, Circulation.